论文部分内容阅读
增生性玻璃体视网膜病变 (ProliferativeVitre oretinopathy ,PVR)是一种常见的严重致盲性眼病 ,是玻璃体视网膜手术后的主要并发症。脂质体(liposome)是一种新型的药物技术 ,已在眼科得到广泛运用。本文仅就脂质体在PVR治疗中的现状和前景作一综述。一、眼用脂质体的结构和作
Proliferative Vitreoretinopathy (PVR) is a common and severe blinding eye disease and is a major complication after vitreoretinal surgery. Liposomes are a new class of drug technology that is widely used in ophthalmology. This article reviews the status and prospects of liposomes in the treatment of PVR. First, the structure and purpose of ophthalmic liposomes